The Lancet, Volume 355, Issue 9221 , Pages 2089 - 2090, 17 June
2000 doi:10.1016/S0140-6736(00)02370-9Cite or Link Using DOI
Strengths and weaknesses of leprosy-elimination campaigns
Multidrug therapy (MDT) for leprosy, introduced in the 1980s,
has sharply reduced the prevalence of the disease (which is
based on the number of patients registered for treatment),
largely by shortening duration of treatment. However, the annual
global case-detection rate remains unchanged at about 700 000
cases. The reduction in number of patients registered for
treatment has lessened the workload of the leprosy services.
Such cost-effectiveness considerations encourage countries to
integrate v ... This article is made available free of charge,
as a service to our users. Please login to access the full
article, or register if you do not yet have a username and
password. Already Registered? Please Login New to TheLancet.com?
TheLancet.com is the online home of: - The Lancet - The Lancet
Diabetes & Endocrinology - The Lancet Infec